Topical treatment of cutaneous ptosis: Endolift® treatment with 1470-nm wavelength Eufoton® LASEmaR®1500

Abstract

This study was designed to evaluate the efficiency of Endolift®, a novel minimally invasive outpatient laser procedure, for the treatment of cutaneous ptosis. Thirty patients aged 25 to 60, 25 women and 5 men, were enrolled on this study. Twenty women got skin ptosis after pregnancy, while 5 women and 5 men got skin laxity after losing body weight. Patients have undergone a single treatment under local anaesthesia. Treatment was performed using the Endolift® procedure, which consists of the laser Eufoton® LASEmaR® 1500. This device uses a 1470 nm wavelength laser lead by micro-optical fibres of different calibres directly inside the skin. Optimal results were obtained in 70% of patients, 18% had good results, and 12% reported moderate results. No patients reported any hematoma. Ten patients took analgesics for a maximum of two days; 5 reported pain resolved after 7 days. In addition, 8 patients reported their first results after 7 to 20 days improving results over time. The follow-up was done after 1, 3, 6 and 12 months when all patients overcame the expected result. No side effect was recorded. These data confirm that Endolift® is a safe and effective procedure for cutaneous ptosis representing a new category for body treatments and a real alternative to surgery.